Catalyst Dossier · compiled by CeliA 🧫

Syndax Pharmaceuticals, Inc. (SNDX)

Pharmaceutical Preparations · market cap $1.7B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Syndax Pharmaceuticals (SNDX) is a ~$1.9B market cap oncology-focused biopharma with 270 employees. Its lead asset, revumenib, is in Phase 3 for colorectal cancer, while its broader pipeline spans AML, NSCLC, breast cancer, ovarian cancer, and chronic graft-versus-host disease across multiple Phase 2 programs. The company carries $130.9M in cash against a net debt position of $213.1M, implying a runway of roughly 7–8 months absent new financing.

The catalyst path

2026-08-03Earningsimp 5/10

Pipeline

Asset	Phase	Indication
cobicistat	Phase 2	Acute Myeloid Leukemia
Erlotinib	Phase 2	Non-Small-Cell Lung Carcinoma
entinostat	Phase 2	Non-Small Cell Lung Cancer
Aromatase Inhibitor (AI) Therapy	Phase 2	ER+ Breast Cancer
Revumenib	Phase 3	Colorectal Cancer
Intensive Chemotherapy Regimen	Phase 3	Acute Myeloid Leukemias
avelumab	Phase 2	Epithelial Ovarian Cancer
exemestane	Phase 2	Breast Cancer
Axatilimab	Phase 2	Chronic Graft-versus-host-disease

Price & technical context

3-month

-8.6%

6-month

+5.2%

12-month

+142.4%

52-wk range

$8.73–$25.15

vs 50-day MA

+10.0%

vs 200-day MA

+10.6%

Realized vol

76.4%

Max drawdown

-64.8%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SNDX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.